Illinois Municipal Retirement Fund Increases Stock Position in Zimmer Biomet Holdings, Inc. $ZBH

Illinois Municipal Retirement Fund boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 113,543 shares of the medical equipment provider’s stock after purchasing an additional 7,344 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Zimmer Biomet were worth $11,184,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Key Financial Inc boosted its stake in shares of Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 163 shares during the period. Cullen Frost Bankers Inc. lifted its position in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC grew its stake in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet in the third quarter valued at approximately $31,000. Finally, Mather Group LLC. purchased a new stake in shares of Zimmer Biomet during the third quarter worth approximately $36,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Johnson Rice set a $112.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, November 5th. Barclays lowered their target price on shares of Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating on the stock in a report on Thursday. JPMorgan Chase & Co. reissued a “neutral” rating and set a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Robert W. Baird restated a “neutral” rating and issued a $100.00 price objective (down previously from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Finally, Sanford C. Bernstein boosted their target price on Zimmer Biomet from $97.00 to $99.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $106.20.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q4 beat and buyback — ZBH topped estimates on revenue and EPS, and the company announced a new buyback that pushed the stock higher after results. Positive near-term cash-return and sales momentum were highlighted. Article Title
• Positive Sentiment: Buy-side upgrade — BTIG Research issued a “Buy” on ZBH, supporting upside sentiment among some investors. Article Title
• Positive Sentiment: Index inclusion/lift — Coverage noted ZBH’s results helped lift the Russell 1000 Healthcare index, signaling industry-level recognition of the quarter. Article Title
• Neutral Sentiment: Analyst price-target moves — Citigroup and Wells Fargo raised ZBH price targets to $98 while keeping neutral/equal-weight ratings, which signals modest upside but not a broad bullish repositioning. Article Title
• Neutral Sentiment: Hold reaffirmation — Needham reaffirmed a “Hold” on ZBH, reflecting mixed analyst conviction despite the beat. Article Title
• Neutral Sentiment: Sector context — A MarketBeat piece comparing healthcare earnings highlights peers (e.g., AstraZeneca) outperforming in profit growth, which provides cross-checks for relative performance but is not company-specific. Article Title
• Negative Sentiment: Guidance caution from salesforce changes — Deep-dive coverage flagged a U.S. salesforce overhaul that prompted management to strike a measured tone on FY26 guidance, introducing execution risk that likely weighs on the stock today. Article Title
• Negative Sentiment: Measured tone on guidance in the earnings call — Transcripts and coverage emphasize that while Q4 beat, management set cautious FY26 commentary and guidance range, which may limit investor upside until execution is clearer. Article Title

Zimmer Biomet Stock Down 0.5%

ZBH stock opened at $95.14 on Friday. The company has a current ratio of 1.98, a quick ratio of 1.39 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $90.05 and its 200 day moving average price is $95.64. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44. The company has a market cap of $18.85 billion, a P/E ratio of 26.87, a P/E/G ratio of 2.71 and a beta of 0.62.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same period last year, the firm earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Tuesday, December 30th. This represents a $0.96 annualized dividend and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.